Jerome Tannenbaum

Sanderling Renal Services-USA LLC ("SRS-USA") is a Delaware Limited Liability Company that was formed in 2012. It began operations in January 2013 by developing a 16 station dialysis clinic in Holdenville, Oklahoma. Since then the Company has opened 6 additional dialysis clinic locations, and has 3 more under construction. The Company is seeking additional capital for expansion. The Company's founder, Jerome Tannenbaum, M.D., Ph.D., FACP was the founder, CEO, and Chairman of three prior, highly successful, national dialysis companies in the United States. Each of the three prior companies were built, over a period of five to seven years, to a substantial size. The first was acquired by Gambro for approximately $400 Million USD in 1995, the second was acquired by Renal Care Group (NYSE: RCG) in 2004 for $385 Million USD, and the third was acquired by Davita (NYSE:DVA) for $725 Million USD in 2010. Dialysis is a treatment that is required by patients with End Stage Renal Disease (ESRD). ESRD afflicts more than 450,000 patients in the United States. (There are currently 300,000 people in China who are receiving dialysis.)The need in the United States is projected to be more than 600,000 people by the end of 2020. (An estimated 1.2 million people would require this service in China if it were universally available). Dialysis patients must receive treatments three times per week. If the patient does not receive treatment he or she will die in a relatively short period of time. In the United States,dialysis is paid for by the Government under the Medicare and Medicaid programs. Essentially all patients are insured, regardless of age. Since patients require treatment on a regular basis in order to remain alive, a dialysis clinic has an extremely predictable recurring revenue stream. The average patient revenue to a dialysis clinic in the United States is approximately $40,000 per year per patient. A clinic with 40 patients will have a very predictable revenue of approximately $1.6 Million per year. The EBITDA margin is approximately 20% of revenue in most clinics if the clinic is operating at 65% or more occupancy. Each clinic requires approximately $1.4 Million USD to finance the equipment, start-up losses for 3 years, and long-term working capital. The highly predictable revenue and cost structure of dialysis creates a long-term cash flow opportunity for an potential return of 15% per year on the investment.